TRACON Pharmaceuticals Inc (NASDAQ:TCON)
| 0.2039 BATS BZX Real-Time Price As of 12:16pm ET |  -0.0006 / -0.29%Today’s Change | 0.13 Today|||52-Week Range 2.19 | -86.32% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Pharmaceuticals: Major | MARKET CAP $6.0M |
Company Description
TRACON Pharmaceuticals, Inc. engages in the development and commercialization of targeted therapies for cancer, and ophthalmic and fibrotic diseases. Its products include TRC105, an anti-endoglin antibody for the treatment of solid tumor types, TRC205 created for the treatment of fibrotic diseases, and TRC102, a small molecule that is in clinical development made for lung cancer and glioblastoma. The company was founded in October 2004 and is headquartered in San Diego, CA.
Contact Information
TRACON Pharmaceuticals, Inc. 4350 La Jolla Village Drive San Diego California 92122-1243 |
Employees
Shareholders
| Individual stakeholders | 31.30% |
| Other institutional | 27.74% |
| Mutual fund holders | 2.34% |
Top Executives
| Charles P. Theuer | President, Chief Executive Officer & Director |
| Scott B. Brown | Chief Financial Officer |
| James L. Freddo | Chief Medical Officer |
| Brenda Marczi | Senior Vice President-Regulatory Affairs |
